Earendil Labs Announces $787 Million in Financing to Scale AI-Driven Biologics Discovery and Development

The funding will accelerate Earendil Labs’ AI-driven R&D platform, expand its interdisciplinary teams, and advance a growing pipeline of antibody and biologics programs, with the goal of delivering first-in-class and best-in-class therapies for patients with serious diseases.